This product is developed with periplaneta americana and is used for the treatment of chronic hepatitis B. The preclinical pharmacological test showed that this product inhibited the replication of DHBV-DNA in DHBV-infected duck serum, reduced the ALT activity of Tupaia belangeri infected with human hepatitis B virus, improved the negative conversion rate of HBeAg, and had certain recovery ability for the liver parenchymal damage. The secretion of HBeAg in 2215 cells was inhibited in vitro. It increased the activity of serum lysozyme and the proliferation of spleen lymphocytes induced by Con-A in mice. It had a certain protective effect on acute liver injury induced by D-galactose in mice and chronic liver injury induced by CCl4 in rats.
Dosage and administration: oral, 2 capsules/time, twice daily
Adverse reactions: In the clinical studies, individual patients developed mild nausea symptoms which spontaneously relieved after 3-5 days, and its relationship with this product is uncertain.
Warnings and Precautions: No research data on pregnant women, children, the elderly and other specific populations
Reference specification: YBZ04142005-2011Z
Approval No. : SFDA Approval No. Z20050113
Marketing Authorization Holder: Company Name: Kunming Sinoway Pharmaceutical Co.Ltd.